Matching articles for "Namzaric"
Drugs for Dementia
The Medical Letter on Drugs and Therapeutics • March 30, 2026; (Issue 1751)
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia,...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)
The Medical Letter on Drugs and Therapeutics • March 30, 2026; (Issue 1751)
...
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • August 22, 2022; (Issue 1657)
...
View the Comparison Table: Drugs for Alzheimer's Disease
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • August 22, 2022; (Issue 1657)
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • September 25, 2017; (Issue 1530)
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive loss is also associated with
other neurological conditions such as Parkinson's
disease, dementia with Lewy bodies, vascular...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive loss is also associated with
other neurological conditions such as Parkinson's
disease, dementia with Lewy bodies, vascular dementia,
and frontotemporal dementia.
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • September 25, 2017; (Issue 1530)
...
View the Comparison Table: Drugs for Alzheimer's Disease
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • July 20, 2015; (Issue 1473)
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase...
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase inhibitor, for treatment of
moderate to severe Alzheimer's type dementia in
patients previously stabilized on both drugs. The
patent for Namenda has recently expired and generic
formulations of memantine 5- and 10-mg tablets have
been approved.